[English]  [Pусский]  [中文]  
ctt-journal > Tiganova et al. (Abstract)

Tiganova et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract33

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment


Childhood acute myeloid leukemia: treatment experience with the AML-BFM-2004 protocol in Morozov Children’s Hospital

Olga A. Tiganova, Konstantin L. Kondratchik, Olga U. Mutorova, Olga U. Fuks, Gleb O. Bronin, Maria A. Maltseva, Ivan I. Tomilin, Tatiana J. Makhortykh, Natalya V. Nepokulchitskaya, Olga L. Kovaliova, Irina B. Alakaeva, Dmitriy B. Lavrukhin, Alexander G. Rumiantsev

Morozov Children’s Hospital, Moscow, Russia

Correspondence: Olga A. Tiganova, Morozov Children’s Hospital, 1, 4th Dobrininskiy per., 119049, Moscow, Russia, E-mail: svudy@spam is badyandex.ru


Introduction: Clinical trials have improved the treatment results of acute myeloid leukemia (AML) during the last 30 years. However, these results are still worse than expected. Immunophenotypic, cytogenetic, and molecular studies indicate that AML is a heterogeneous group and stress the need for risk-adapted treatment.

Methods: Since 2005, children with AML, excluding those with acute promyelocytic leukemia, have been treated with the AML-BFM-2004 protocol in the hematology department of the Morozov Children’s Hospital. The program is used to improve complete remission and event-free survival (EFS) rates by using a double induction regimen, strong therapy timing, and a differentiated approach, taking into account the risk group and FAB variant, including hematopoietic stem cell transplantation (HSCT).

Results: Our retrospective analysis included 46 patients under 18 years of age with AML and no prior malignancies or treatment. The median follow-up period was 32 months. The complete remission (CR) rate was 82.6%. Three patients (6.5%) did not achieve remission. Five patients (10.9%) died during induction phase and 1 patient died in CR. AML relapse developed in 6 patients. At last follow-up 30 patients (65.2%) were in continuous complete remission (CCR).

Conclusion: Our experience with the AML-BFM-2004 protocol demonstrates promising results for this intensive risk-adapted approach in children with AML.

Keyworlds: acute myeloid leukemia, children, AML-BFM-2004 protocol